Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FENOX: Fexuprazan Co-therapy in Patients Receiving NOACs
NCT07497893Not yet recruiting
- Sponsor
- Ewha Womans University Mokdong Hospital
- Start
- Dec 2026
- Primary completion
- Nov 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of fexuprazan in upper gastrointestinal bleeding (UGIB) (2 arms), sponsored by Ewha Womans University Mokdong Hospital. Primary endpoint: Clinically relevant upper gastrointestinal bleeding at 12 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
fexuprazan
03
Conditions
upper gastrointestinal bleeding (UGIB)
Beyond the preview
Go deeper on NCT07497893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07497893.